As the Number of Analytical Monitoring Tests for Biopharmaceuticals
Skyrockets, Waters Builds Intelligence into a Fit-for-Purpose System
MILFORD, Mass.--(BUSINESS WIRE)--Jan. 22, 2019--
Waters Corporation (NYSE:WAT) today introduced the BioAccord™ System, a
purposefully designed liquid chromatography-mass spectrometry (LC-MS)
solution that will expand access to high-resolution time-of-flight mass
spectrometry capabilities to more scientists. The BioAccord System
promises to move routine monitoring out of centralized MS labs and into
the hands of more scientists by enabling more effective analysis of
biotherapeutic protein attributes across development and within quality
This press release features multimedia. View the full release here:
Waters Expands Accessibility to High Resolution MS Data with the First SmartMS-Enabled LC-MS Biopharma System (Photo: Business Wire)
"The pace of innovation in the biopharmaceutical industry is
accelerating, and with it, the monitoring requirements for
biotherapeutics are growing exponentially," said Chris O'Connell,
Chairman and CEO, Waters Corporation. "The inherent complexity of these
therapies, combined with rising regulatory standards, are driving more
intensive and widespread testing requirements. Waters designed the
BioAccord System as a fit-for-purpose LC-MS biopharmaceutical solution
to deliver rich mass spectrometry data for improved productivity and
The BioAccord System pairs ACQUITYTM UPLC™ I-Class Plus with
the newly-developed ACQUITY RDa™ Detector featuring SmartMS™. This
system offers new levels of user experience with automated setup and
self diagnosis delivered through an intuitive user interface, all within
a surprisingly small footprint. Powered by UNIFI™, Waters’
compliance-ready LC-MS informatics platform, the BioAccord System has
been optimized for intact protein, released glycan, and peptide
monitoring applications, and streamlined by the use of Waters'
application-specific chemistries and consumables kits.
The first public exhibition of the BioAccord System will take place at
Characterized Biopharmaceutical Conference (WCBP) in Washington D.C.
On Tuesday, January 29, at WCBP, Waters will sponsor a lunch seminar in
the Palm Court Room at the Mayflower Hotel from 12:45 – 1:45 p.m.
titled: High Performance LCMS Analysis in Biopharma: From Molecular
Characterization to Routine Monitoring featuring Dr. John Gebler,
Director, Biopharmaceutical, Waters Corporation. Guest speaker, Dr.
Mellisa M. Ly, Principal Scientist from Pfizer, Inc. will expand on the
topic presenting, Characterizing and Monitoring Quality Attributes in
Monoclonal Antibodies using a High Resolution, Small Footprint LC-MS
Additionally, customers are invited to visit www.waters.com/bioaccord
for a deeper understanding of the new BioAccord LC-MS system.
The BioAccord System is currently available for customer shipments
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), the world's leading specialty measurement
company, has pioneered chromatography, mass spectrometry, and thermal
analysis innovations serving the life, materials, and food sciences for
more than 60 years. With approximately 7,000 employees worldwide, Waters
operates directly in 31 countries, including 15 manufacturing
facilities, and with products available in more than 100 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005306/en/
Source: Waters Corporation